May 8, 2024 07:30 AM EDT
R&D

Te­va’s an­tipsy­chot­ic as­set pass­es Phase 3 test in schiz­o­phre­nia

Ayisha Sharma

News Reporter

Te­va said Wednes­day morn­ing that its schiz­o­phre­nia drug suc­ceed­ed in a Phase 3 tri­al with signs of a dif­fer­en­ti­at­ed safe­ty pro­file ver­sus stan­dard of care …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times